Quantcast
Last updated on April 18, 2014 at 10:03 EDT

Latest Tigecycline Stories

2013-10-11 23:25:47

The United States Food and Drug Administration (FDA) has recently issued a Drug Safety Announcement and approved a Black Box Warning, one of the harshest warnings, for Pfizer’s antibiotic intravenous (IV) drug Tygacil®. In particular, the FDA warns prescribing doctors and consumers that use of the IV drug Tygacil® is associated with an increased risk of death in comparison to other antibiotic drugs and that the IV antibiotic Tygacil® should only be used in situations where...

2013-10-08 12:27:18

However, Hospital Pharmacy Directors Are Less Receptive to Formulary Inclusion Of Such Premium-Priced Antibiotics, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 8, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a majority of surveyed infectious disease (ID) specialists are willing to prescribe novel antibiotics, developed under the Infectious Diseases...

2013-09-30 23:02:42

The U.S. Food and Drug Administration reports it has notified health professionals about a new Black Box warning for Pfizer Inc.'s intravenous antibacterial drug Tygacil (tigecycline). The FDA says the warning ramp-up is based on additional analysis the regulator conducted on the drug that reveals it is causing an increased mortality rate among users, Parker Waichman LLP cautions. New York, New York (PRWEB) September 30, 2013 Parker Waichman LLP, a national law firm dedicated to...

2013-06-12 08:29:45

EU5 Payers Indicate that Tightening Budgets Mean Emerging Brands Must Demonstrate Compelling Cost-Effectiveness Over Current Therapies in Order to Justify Reimbursement at a Premium Price, According to a New Report from Decision Resources BURLINGTON, Mass., June 12, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than half of surveyed physicians from the EU5 (France, Germany,...

2012-09-18 02:26:43

ANN ARBOR, Mich., Sept. 18, 2012 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious diseases and unmet medical needs, today announced that it has initiated efforts to develop a monoclonal antibody (mAb) therapy for the treatment of acinetobacter infections. Many strains of Acinetobacter are multidrug-resistant and pose an increasing global threat to hospitalized patients, wounded military personnel and those...

2012-05-17 09:36:22

Multidrug-resistant pathogens are becoming more frequent, and the few "last resort" treatments available for infections with these bacteria have also shown an increase in use in recent years, according to a study published May 16 in the open access journal PLoS ONE. The authors, led by Makoto Jones of the Veterans Affairs Salt Lake City Health Care System, investigated the use of two such antibiotics, polymyxins and tigecycline, in 127 Veterans Affairs medical centers between 2005 and...

2011-11-14 23:17:33

Clinician-scientists in the Princess Margaret Cancer Program have found a promising approach to treating leukemia, using an old drug in a new way. The proof-of-concept research published today in Cancer Cell (10.1016/j.ccr.2011.10.015) describes how the Canadian team discovered that the antibiotic tigecycline targets and destroys leukemia stem cells by cutting off the cell's energy production. "If you think of all the cells in the body as a power grid, we've discovered that tigecycline...

2010-10-15 07:00:00

CHAPEL HILL, N.C., Oct. 15 /PRNewswire/ -- Cempra Pharmaceuticals today announced poster presentations on its novel fluoroketolide antibiotic, solithromycin (CEM-101), and the Company's proprietary front-loading oral dosing regimen of sodium fusidate, TAKSTA (CEM-102) at the 48th Annual Meeting of the Infectious Diseases Society of America in Vancouver, British Columbia. All presentations are scheduled for 10 a.m. to 6 p.m. PDT on Friday, October 22. Solithromycin (CEM-101) The...

2010-10-06 08:00:00

MALVERN, Pa., Oct. 6 /PRNewswire/ -- Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that methicillin-resistant Staphylococcus aureus (MRSA) is the most concerning pathogen to surveyed U.S. physicians with regard to their treatment of skin and skin structure infections. A drug's activity against MRSA is among the top factors that influences U.S. physician drug selection for treating skin and skin...

2010-03-23 11:55:00

CLEVELAND, March 23 /PRNewswire/ -- Magellan Biosciences, Inc., an emerging leader in clinical diagnostics products, announced that the company has become the first to offer minocycline and telavancin on IVD-labeled microbroth dilution susceptibility plates. The U.S. Food and Drug Administration (FDA) has cleared TREK-brand Sensititre MIC plates for testing minocycline against Gram positive and Gram negative bacterial isolates, as well as telavancin against Gram positive bacterial isolates...